Cannabis Law Report

FEBRUARY 10, 2022

Court of Appeals for the Ninth Circuit dismissed a petition for review of a Drug Enforcement Administration (DEA) response to an attorney’s letter seeking advice and guidance on how a physician could administer psilocybin to a terminally ill patient without incurring liability under the Controlled Substances Act (CSA). By Allison Campbell.

DEA 52

DEA Clinical Trials Policy Research and Development 52

SpeedWeed

AUGUST 11, 2021

According to Dr. Sue Sisley, President of the Scottsdale Research Institute and longtime cannabis researcher, this new study is sorely needed in the community. Veterans are demanding objective cannabis drug development research, and the state of Michigan is fulfilling our collective obligation to our beloved Veteran community.”.

Clinical Trials 52

Clinical Trials Research and Development Pharmaceutical DEA 52

Cannabis Law Report

OCTOBER 5, 2021

The drug has previously been used with some success in clinical trials designed to treat depression. These trials typically involve the use of music playlists to support the psychedelic experience. The team now plan to investigate the effect of music on the brain while under the influence of psilocybin using an MRI scanner.

Clinical Trials 52

Clinical Trials Research and Development DEA Therapy 52

Cannabis Law Report

AUGUST 18, 2022

Smith , a partner with the firm and co-leader of the firm’s Life Sciences & Health Effects Team, will lead the practice, bringing together scientist-attorneys and experienced litigators to support clients that are driving innovation in mental health treatments. BUFFALO, N.Y. , Aug. Phillips Lytle Special Counsel Kyle W.

Therapy 52

Therapy Research and Development Pharmaceutical Treatment 52

Cannabis Law Report

JULY 9, 2021

Not only are more and more jurisdictions decriminalizing the use of psychedelics for recreational purposes, but it appears that psychedelic substances are the new horizon for the treatment of severe psychological disorders and other ailments. Psychedelic therapy is not a fringe phenomenon.

Law 105

Law Therapy Clinical Trials Research and Development 105

MedicalJane

JUNE 29, 2018

On June 26, 2018, the FDA granted approval of Epidiolex, a cannabidiol (CBD) oral solution, to GW Research Ltd (GW). The new drug is indicated for the treatment of seizures associated with two rare and severe forms of epilepsy, Lennox-Gastaut syndrome and Dravet syndrome, in patients two years of age and older.

Clinical Trials 53

Clinical Trials CBD DEA Research and Development 53

Veriheal

JUNE 24, 2021

health official reportedly slammed “ongoing federal restrictions that are inhibiting research into marijuana”. The Senator stated that the NIH has been reporting on “potentially promising peer-reviewed clinical research” and asked for an update on how the NIH was planning to proceed and navigate issues. .

Research and Development 52

Research and Development Clinical Trials Treatment Access 52

CannaMD

AUGUST 8, 2020

Researchers believe cannabis contains over 100 unique chemical compounds! Drugs, substances, and certain chemicals used to make drugs are classified into five categories (known as schedules ) depending on the Department of Drug Enforcement Agency (DEA)’s definition of the drug’s acceptable medical use and abuse/dependency potential.

CBD 99

CBD DEA Research and Development Hemp 99

The Cannigma

MAY 1, 2023

Named because it is the result of the joining two different chemical types – a ketone and an amine, ketamine was developed in 1962 as an alternative dissociative anesthetic drug to the potently hallucinogenic phencyclidine, known more commonly as PCP. It was becoming clear that another class of anesthetics was needed.

Blood Pressure 80

Blood Pressure Chronic Pain Research and Development Clinical Trials 80

Veriheal

AUGUST 31, 2020

We are humbled to introduce you to them and their exceptional ideas, ranging from community grassroots mental health efforts designed to empower historically vulnerable communities of color, to research plans for identifying strain specific genetics. Veriheal’s Innovation in Cannabis Scholarship 2020 Winners . Nishtha Tripathi.

Research and Development 117

Research and Development Education Agriculture Patients 117

Weedistry

MARCH 7, 2019

Marijuana Fights Cancer and Helps Manage Side Effects, Researchers Find. She had been screening brain cancer cells because they grow faster than normal cell lines and thus are useful for research purposes. The ID -1 gene is active during human embryonic development, after which it turns off and stays off.

THC 40

THC CBD Clinical Trials Research and Development 40

SpeedWeed

MARCH 5, 2021

One, they have been determined by the US Food and Drug Administration to be clinically safe and effective treatments for a specific medical condition. Two, they are federally classified by DEA and HHS as Schedule II, III, IV or V substances. Rescheduling cannabis will not necessarily facilitate clinical research.

Business 52

Business Policy Clinical Trials Research and Development 52

Veriheal

JUNE 29, 2021

Did we ever stop to think that if we could legally utilize the plants in the first place that perhaps we wouldn’t develop terminal illnesses at such a high rate? The lawsuit came after the DEA denied their application to utilize a synthetic form of psilocybin under the RTT laws. Introducing the Right to Try Act.

Therapy 55

Therapy DEA Patients Clinical Trials 55

Canna Law Blog

NOVEMBER 6, 2021

Once off-limits because of federal prohibition, a trickle of research from the 1990s has grown into a stream. But despite increasing acceptance by the public, and commercial investment in psychedelic therapies, aging federal laws stem the flow of vital research. Research was permitted in the mid-20th century, until the law stepped in.

Clinical Trials 98

Clinical Trials DEA Research and Development Therapy 98

Canna Law Blog

MAY 7, 2020

At the same time, because of the federal illegality of cannabis, the federal government has routinely denied third party requests for further research in regards to its potential medical benefits, among other health and safety impacts. These cannabis products are used by researchers in the U.S.

DEA 71

DEA Research and Development Cultivation Supply Chain 71

Cannabis Law Report

APRIL 13, 2022

North American Industry Leader in Psychedelic Therapy and Research. Complementary businesses combine to create a preeminent North American platform with operations spanning 13 wellness clinics, four research sites and one bioanalytical laboratory. Watch Video: The Press Release. NEWS PROVIDED BY. Numinus Wellness Inc. .

Clinical Trials 52

Clinical Trials Research and Development Therapy Treatment 52

Canna Law Blog

MARCH 4, 2020

From 2015 to 2018, the number of clinics increased from 60 to 300; that number is undoubtedly higher today. People are increasingly using ketamine for ailments that resist treatment through traditional pharmaceutical drugs.

Therapy 89

Therapy Legalization Chronic Pain DEA 89

Cannabis Law Report

APRIL 8, 2022

as a non-profit organization to fulfill the need to broaden psychedelic research, therapy, and develop legal options for psychedelic medicine. Rick Doblin founded MAPS as an official 501(c)(3) non-profit research organization on April 8, 1986. Later that year, Doblin sued the DEA for the first time.

Clinical Trials 52

Clinical Trials Therapy Research and Development DEA 52

Canna Law Blog

MARCH 4, 2020

From 2015 to 2018, the number of clinics increased from 60 to 300; that number is undoubtedly higher today. People are increasingly using ketamine for ailments that resist treatment through traditional pharmaceutical drugs.

Legalization 52

Legalization Therapy Chronic Pain DEA 52

Cannabis Law Report

JULY 12, 2019

By: James Holley, Molecular Biologist, Scientific Officer, Mike Robinson, Co-founder, Research Institute, and Dr. David Ostrow, M.D., Research Director. International Cannabinoid Cancer Research Institute (Draft 5). Things seemed to go well in animal trials using URB597. (21)

Extraction 73

Extraction Pharmaceutical CBD Epilepsy 73

SpeedWeed

DECEMBER 28, 2018

There’s nothing to justify the sky-high price (about $90 per day) beyond the cost of research and development to win FDA approval. But there’s nothing to justify the sky-high price (about $90 per day) beyond the cost of research and development to win FDA approval and Big Pharma’s insatiable thirst for profits.

Pharmaceutical 40

Pharmaceutical Research and Development Legalization CBD 40